Webinar Details
In this free live webinar, we will cover:
Contractility tracking plus fluorescent readouts (calcium, voltage, or any reporter) in 96-well 3D tissue plates — fewer instruments, more answers per experiment.
New Curi Bio 96-well tissue plate: >95% automation-ready casting success on standard liquid handlers — built for the throughput a real screening workflow demands.
A newly scaled Stingray, natively paired with Nautilai Plus — acute, chronic, or scheduled stimulation, autonomous in the incubator.
Up to 384-well fluorescence imaging across 2D cultures, organoids, and 3D tissues — one instrument that scales with your science.Join this webinar for the opportunity to learn more and join the live Q&A.
Summary
The Nautilai Plus ecosystem is here — and it changes what functional biology can accomplish in a single workflow.
Curi Bio's new flagship platform pairs 96-well contractility tracking with high-throughput fluorescence imaging — calcium, voltage, or any fluorescent reporter — across 2D cultures, organoids, and 3D engineered tissues, up to 384 wells. Anchored by the new 96-well tissue plate (automation-ready, >95% casting success on standard liquid handlers) and a newly scaled Stingray stimulator, the platform synchronizes acute, chronic, and scheduled stimulation with multimodal readouts on the same plate.
What that unlocks: 3D tissue contractility as a routine 96-well endpoint. Compound screens on organoids and monolayers at 384-well scale — no dedicated instrument required. Mechanistic questions that once spanned three experiments, resolved in one.
In 30 minutes, Dr. Thomas Leahy and Dr. Christos Michas walk through the platform and the data behind it — cardiotoxicity and MYBPC3 phenotyping in iPSC-derived cardiomyocytes, AAV capsid screening in 3D engineered skeletal muscle and CNS dose-response in 384-well brain organoids. Plus a live Q&A and a look ahead to what ships today.
Date & Time
Wednesday, June 24, 2026 at 8:00-9:00am PT (11:00am ET / 5:00pm CET)